|
Sign In to gain access to subscriptions and/or personal tools.
|
Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin
Gabriela Maria Pavan de Arruda Camargo
Department of Physiology, Paulista State University, UNESP, gabriela.camargo@ gmail.com
Wilson Abrão Saad
Department of Physiology, Paulista State University, UNESP, Department of Physiology, Federal University of São Carlos, UFSCAR, University of Taubaté, UNITAU, University of Araraquara, UNIARA
Luiz Antônio de Arruda Camargo
Department of Physiology, Paulista State University, UNESP, Department of Physiology, Federal University of São Carlos, UFSCAR, Department of Physiology, Federal University of São Carlos, UFSCAR
Introduction. Brain arginine 8-vasopressin (AVP), through the V1a- and V2-receptors, is essential for the maintenance of mean arterial pressure (MAP). Central AVP interacts with the components of the renin-angiotensin system, which participate in MAP regulation. This study aimed to determine the effects of V1a-, V2- and V1a/V2-AVP selective antagonists and AT1- and AT2-angiotensin II (Ang II) selective antagonists on the MAP induced by AVP injected into the medial septal area (MSA) of the brain.
Materials and methods. Male Holtzman rats with stainless steel cannulae implanted into the MSA were used in experiments. Direct MAP was recorded in conscious rats.
Results. AVP administration into the MSA caused a prompt and potent pressor response in a dose-dependent fashion. Pretreatment with the V1a- and V2-antagonists reduced, whereas prior injection of the V1a/V2-antagonist induced a decrease in the MAP that remained below the baseline. Both AT 1- and AT2-antagonists elicited a decrease, while simultaneous injections of two antagonists were more effective in decreasing the MAP induced by AVP.
Conclusion. These results indicate there is a synergism between the V1a- and V2-AVP and AT1and AT2-Ang II receptors in the MSA in the regulation of MAP.
Key Words: AT1- and AT2-receptors medial septal area median arterial pressure V1a- and V2-receptors vasopressin
References
- Berecek KH, Mah SC, Baum P., Hofbauer KG Cardiovascular effects of intracerebroventricular injection of vasopressin in unanaesthetized normotensive and DOCA-salt hypertensive rats. J Hypertens Suppl 1984;2:29-31.[Medline]
[Order article via Infotrieve]
- Unger T., Rohmeiss P., Becker H., Ganten D., Lang RE, Petty M. Sympathetic activation following central vasopressin receptor stimulation in conscious rats. J Hypertens Suppl 1984;2:25-7.[Medline]
[Order article via Infotrieve]
- Berecek KH, Olpe HR, Jones RS, Hofbauer KG Microinjection of vasopressin into the locus coeruleus of conscious rats. Am J Physiol 1984;247:675-81.
- Dorsa DM, Brot MD, Shewey LM, Meyers KM, Szot P., Miller MA Interaction of a vasopressin antagonist with vasopressin receptors in the septum of the rat brain. Synapse 1988;2:205-11.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dorsa DM, Majumdar LA, Petracca FM, Baskin DG, Cornett LE Characterization and localization of 3H-arginine8-vasopressin binding to rat kidney and brain tissue. Peptides 1983;4:699-706.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Poulin P., Lederis K., Pittman QJ Subcellular localization and characterization of vasopressin binding sites in the ventral septal area, lateral septum, and hippocampus of the rat brain. J Neurochem 1988;50:889-98.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shewey LM, Boer GJ, Szot P., Dorsa DM Regulation of vasopressin receptors and phosphoinositide hydrolysis in the septum of heterozygous and homozygous Brattleboro rats. Neuroendocrinology 1989;50:292-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shewey LM, Brot MD, Szot P., Dorsa DM Enhanced phosphoinositol hydrolysis in response to vasopressin in the septum of the homozygous Brattleboro rat. Brain Res 1989;478:95-102.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shewey LM, Dorsa DM Enhanced binding of 3H-arginine8-vasopressin in the Brattleboro rat. Peptides 1986;7:701-04.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Berecek KH, Webb RL, Brody MJ Evidence for a central role for vasopressin in cardiovascular regulation. Am J Physiol 1983;244:852-9.
- Martin SM, Malkinson TJ, Veale WL, Pittman QJ The action of centrally administered arginine vasopressin on blood pressure in the conscious rabbit. Brain Res 1985;348:137-45.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Budzikowski A., Lon S., Paczwa P., Szczepanska-Sadowska E. Differential effects of V2 vasopressin agonist and antagonists on blood pressure regulation in normotensive (WKY) and spontaneously hypertensive (SHR) rats. J Auton Nerv Syst 1992;39:87-95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hasser EM, Bishop VS Reflex effect of vasopressin after blockade of V1 receptors in the area postrema. Circ Res 1990;67:265-71.[Abstract/Free Full Text]
- Walker BR, Childs ME, Adams EM Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol 1988;255:261-5.
- Serradeil-Le Gal C., Herbert JM, Delisee C. et al. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells. Am J Physiol 1995;268:404-10.
- Fernandes S., Bruneval P., Hagege A., Heudes D., Ghostine S., Bouby N. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 2002;143:2759-66.[Abstract/Free Full Text]
- Jöhren O., Imboden H., Häuser W., Maye I., Sanvitto GL, Saavedra JM Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus. Brain Res 1997;757:218-27.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tamura K., Yokoyama N., Sumida Y. et al. Tissue-specific changes of type 1 angiotensin II receptor and angiotensin-converting enzyme mRNA in angiotensinogen gene-knockout mice. J Endocrinol 1999;160:401-08.[Abstract]
- Bunnemann B., Fuxe K., Ganten D. The brain renin-angiotensin system: localization and general significance. J Cardiovasc Pharmacol 1992;19:51-62.
- Jöhren O., Inagami T., Saavedra JM AT1A, AT1B and AT2 angiotensin II receptor subtypes in rat brain. Neuroreport 1995;6:2549-52.[Web of Science][Medline]
[Order article via Infotrieve]
- Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 1998;78:1-11.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Leung KH, Smith RD, Timmermans BM, Chiu AT Regional distribution of the two subtypes of angiotensin II receptor in rat brain using selective nonpeptide antagonists. Neurosci Lett 1991;123:95-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Häuser W., Jöhren O., Saavedra JM Characterization and distribution of angiotensin II receptor subtypes in the mouse brain. Eur J Pharmacol 1998;348:101-14.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wright JW, Harding JW Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994;18:21-53.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- De Gasparo M., Catt KJ, Inagami T., Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.[Abstract/Free Full Text]
- Paxinos G., Watson C. (eds). The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986:264.
- Laszlo FA, Laszlo FJR, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991;43:3-108.
- Jackson EK, Renin and angiotensin. In: Hardman JG, Limbird LE, Gilman AG (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: MacGraw-Hill, 1996:715-31.
- Yamamura Y., Ogawa H., Chihara T. et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991;52:572-4.
- Mayinger B., Hensen J. Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes 1999;107:157-65.[Web of Science][Medline]
[Order article via Infotrieve]
- Koshimizu TA, Nasa Y., Tanoue A. et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 2006;103:7807-12.[Abstract/Free Full Text]
- Burrell LM, Phillips PA, Stephenson JM, Risvanis J., Rolls KA, Johnston CI Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994;23:737-43.[Abstract/Free Full Text]
- Burrell LM, Phillips PA, Risvanis J., Aldred KL, Hutchins AM, Johnston CI Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 1995;26:828-34.[Abstract/Free Full Text]
- Thibonnier M., Kilani A., Rahman M. et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 1999;34:1293-300.[Abstract/Free Full Text]
- Fujisawa G., Ishikawa S., Tsuboi Y., Okada K., Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993;44:19-23.[Web of Science][Medline]
[Order article via Infotrieve]
- Naitoh M., Suzuki H., Murakami M. et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267:2245-54.
- Tahara A., Saito M., Sugimoto T. et al. Pharmacological characterization of YM087, a potent nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998;357:63-9.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yatsu T., Tomura Y., Tahara A. et al. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 1999;376:239-46.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.[Abstract/Free Full Text]
- Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 1997;18: 383-439.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lon S., Szczepanska-Sadowska E., Szczypaczewska M. Evidence that centrally released arginine vasopressin is involved in central pressor action of angiotensin II. Am J Physiol 1996;270:167-73.
- Han NL, Sim MK Hypothalamic angiotensin receptor subtypes in normotensive and hypertensive rats. Am J Physiol 1998;275:703-09.
- Shelat SG, Reagan LP, King JL, Fluharty SJ, Flanagan-Cato LM Analysis of angiotensin type 2 receptors in vasopressinergic neurons and pituitary in the rat. Regul Pept 1998;73:3-12.
- Li Z., Iwai M., Wu L. et al. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 2003;284:116-21.
Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 3,
133-138 (2008)
DOI: 10.1177/1470320308095260

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|